Regulatory News:

ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2022.

Events

Date*

Cash position and activity update for Q4 2021

February 24, 2022

2021 Annual Results

April 28, 2022

Cash position and activity update for Q1 2022

May 19, 2022

Cash position and activity update for Q2 2022

August 18, 2022

2022 Half Year Results

September 29, 2022

Cash position and activity update for Q3 2022

November 17, 2022

* indicative dates subject to change

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.

NewCap Investor relations Louis-Victor Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53

NewCap Media relations Nicolas Merigeau abionyx@newcap.eu +33 (0)1 44 71 94 98

Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Juin 2022 à Juil 2022 Plus de graphiques de la Bourse Abionyx Pharma
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Juil 2021 à Juil 2022 Plus de graphiques de la Bourse Abionyx Pharma